Text Size A A A

Sun Pharma In The News

Tell a Friend Print Home » Media » Sun Pharma In The News

(D) Pfizer sues Lupin on anti-epilepsy drug

The US-based global pharmaceutical giant Pfizer Inc has filed a second suit against Mumbai-based drumaker Lupin in the US alleging that the latter by attempting to manufacture a generic version of oral solution with pregabalin is infringing the former's patent coverage on its branded drug Lyrica. The second suit on the anti-epilepsy drug relates to a 'solution' that Lupin aims to manufacture while the previous one concerned a 'tablet' version.Pfizer had already filed complaints last year against generic makers including Sun Pharma and Wockhardt apart from Lupin for infringing its patent on Lyrica (pregabalin) in the US district Court of Delaware. The drug clocks revenue worth over $1 billion globally for Pfizer and is also the fastest selling anti-epileptic drug in the market.

Some of the patents related to the drug are scheduled to expire by March 6, 2018.Teva, Sandoz, Actavis, Cobalt Laboratories, Alphapharm are the other generic companies which have been sued by Pfizer on Lyrica patent violations in US.Lyrica (pregabalin) is an oral pill that is chemically related to the other gabapentin grugs like Neurontin and Gabarone. It is used for treating pain caused by neurologic diseases such as postherpetic neuralgia as well as seizures.The US FDA approved pregabalin in December 2004. for use in treating epilepsy, diabetic neuropathy pain and post-herpetic neuralgia and Pfizer started selling it on the US market in fall 2005.In June 2007 the FDA approved Lyrica as a treatment for fibromyalgia. Fibromyalgia is a disorder classified by the presence of chronic widespread pain and a heightened and painful response to gentle touch. Fibromyalgia also include debilitating fatigue, sleep disturbance, and joint stiffness.